Non-alcoholic fatty liver disease in lean individuals
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease, encompassing a spectrum from non-alcoholic fatty liver to non-alcoholic steatohepatitis, which can progress to cirrhosis. It has recently been recognised that NAFLD also occurs in individuals who are not obese, especially in Asian populations. In these patients, NAFLD manifests at lower overall body mass index thresholds in the presence of increased visceral adipose tissue. Currently, the principles of clinical management are similar to those in obese individuals, although, in specific regions and clinical situations, unique aetiologies of NAFLD must be treated specifically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“With respect to common NAFLD findings, lean patients are identical to obese counterparts.(66) The histological studies on NAFLD in common unspecified lean populations are summarized in Table 3.”
ResultSelf-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“Excess body weight, type 2 diabetes and dyslipidaemia are classic risk factors for NAFLD.(2) Although, it is now recognised that the condition exists in those who are not obese, especially in Asia.”
BackgroundTaheri, S., Lin, L., Austin, D., Young, T., & Mignot, E. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010062 · Cited by 2,477 · cited 1×
“JHEP duration and quality of sleep.(113,114) Individuals with snoring or severe early morning fatigue should be evaluated for sleep apnoea.”
BackgroundDynamics of fat cell turnover in humans
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., et al. (2008) · Nature · doi:10.1038/nature06902 · Cited by 2,357 · cited 1×
“Adipocyte size and biological behaviour are additional determinants of metabolic disorders.(37,38) A study examined the relationship between body fat characteristics and insulin resistance in South Asian men (n = 29) compared to Caucasians (n = 18).”
ResultWong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
Association between body-mass index and risk of death in more than 1 million Asians
Zheng, W., McLerran, D. F., Rolland, B., Zhang, X., Inoue, M., Matsuo, K., He, J., Gupta, P. C., Ramadas, K., Tsugane, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010679 · Cited by 885 · cited 2×
“Studies have shown that among Asians, the risk of death is more strongly affected by a low BMI than by a high BMI, when compared with Europeans.(72)”
BackgroundBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Pathogenesis of insulin resistance in skeletal muscle
Abdul-Ghani, M. A., & DeFronzo, R. A. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/476279 · Cited by 670
Mihalik, S. J., Goodpaster, B. H., Kelley, D. E., Chace, D. H., Vockley, J., Toledo, F. G. S., & DeLany, J. P. (2010) · Obesity · doi:10.1038/oby.2009.510 · Cited by 653
Cited by
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757
Lazarus, J. V., Mark, H. E., Villota-Rivas, M., Palayew, A., Carrieri, P., Colombo, M., Ekstedt, M., Esmat, G., George, J., Marchesini, G., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.025 · Cited by 267
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322564 · Cited by 205
Saponaro, C., Sabatini, S., Gaggini, M., Carli, F., Rosso, C., Positano, V., Armandi, A., Caviglia, G. P., Faletti, R., Bugianesi, E., et al. (2022) · Liver International · doi:10.1111/liv.15377 · Cited by 116
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
“Although NAFLD/NASH has usually been associated with obesity, emerging evidence has reported NAFLD/NASH in nonobese humans, with lean patients thought to have the worst phenotype.(159,160) As mentioned earlier, HFrD-induced inflammation and barrier deterioration resulted in steatohepatitis in mice even in the absence…”
BackgroundAntifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
“How can we improve the fibrosis drug discovery process? To mitigate against failure, we must look critically at: (1) how we are selecting drug targets and/or combinations; (2) whether we are utilizing preclinical models (and readouts used to determine drug efficacy) with sufficient proximity to patients; and (3) optim…”
BackgroundWijarnpreecha, K., Li, F., Lundin, S. K., Suresh, D., Song, M. W., Tao, C., Chen, V. L., & Lok, A. S. F. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17424 · Cited by 61
“aOther neoplasms refer to neoplasms that are other than digestive cancers, mainly including (1) C15- C26 Malignant neoplasms of digestive organs; (2) C30- C39 Malignant neoplasms of respiratory and intrathoracic organs; (3) C50- C50 Malignant neoplasms of breast; (4) C69- C72 Malignant neoplasms of eye, brain and othe…”
BackgroundMetabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61
Errafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
Metadata
- Authors
- Albhaisi, S., Chowdhury, A., & Sanyal, A. J.
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 1
- Issue
- 4
- Pages
- 329-341
- ISSN
- 2589-5559 (ISSN-L)
- OpenAlex
- W2970223292
- Cited by
- 174
- References
- 20
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.